Search
Menu

Goal and Learning Outcomes

The goal of this continuing education program is to enhance healthcare providers’ understanding of hereditary cancer syndromes, with emphasis on two of the most common syndromes: hereditary breast/ovarian cancer syndrome (HBOC caused by BRCA1 and BRCA2 gene mutations) and hereditary colon cancer, including Lynch syndrome and polyposis (multiple polyps). After studying the material presented here, you will be able to:
  • List three goals of genetic testing for hereditary cancer syndromes
  • Name three cancers for which there are effective prevention and/or screening interventions for patients at high hereditary risk
  • Identify three limitations of genetic testing for hereditary cancer syndromes
  • Discuss how the interprofessional healthcare team should collaborate to promote educational goals related to three hereditary cancer syndromes

Course Authors

Accreditation Information

NURSES

In support of improving patient care, Relias LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Provider approved by the California Board of Registered Nursing, CEP#13791

 

CEBroker

Relias LLC reports to CEBroker for the following boards (Provider # 50-1489): Arkansas State Board Of Nursing, District Of Columbia Board Of Nursing, Florida Board Of Nursing, Georgia Board Of Nursing, New Mexico Board Of Nursing, South Carolina Board Of Nursing and  West Virginia Board Of Examiners For Registered Professional Nurses

 

Please check the licenses/certifications section under my account (after logging in) to make sure you have entered a valid license number. This information is required for correct reporting of your course completions to CE Broker.

 

Disclosures

None of the planners/faculty, unless otherwise noted, for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.